Recent

% | $
Quotes you view appear here for quick access.

Rosetta Genomics, Ltd. Message Board

  • johngunn51 johngunn51 Apr 12, 2013 10:19 AM Flag

    Litlle Commercial Value

    The microRNA tests have little or no commercial value. Too expensive and esoteric to be widely adapted. That's why the revenues are still so small, even after commercial launch. Very few oncologists are choosing them, even w the professional reps marketing them. The company raised a lot of money- 33mil by touting the product and it's sales potential and this money is disappearing at a rapid rate into lavish lifestyle accounts of Berlin and a handful of other people. It's kind of a scam in my opinion. It seems to me Berlin has not been forthcoming at all in terms of what kind of sales these tests can actually generate. Ironically the only microRNA IP that was of commercial value was given away for 900K to keep the company from filing bankruptcy 2 yrs ago and just flipped by the buyers to evil Monsanto for 39mil. I don't think ROSG will be sold, until Berlin et al have milked the 33mil and the stock is under a buck. Just my opinion, I was long until the CC. Now I have gotten out, taken a loss, and halfway thinking of suing.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
ROSG
1.31-0.02(-1.50%)Apr 29 3:58 PMEDT